As far as SARS-CoV-2 (Severe Acute Respiratory Syndrome-CoronaVirus-2) is mostly reducing the impact, beta-coronavirus and new viruses are now emerging. We begin to understand how the most common symptoms occurs include fever and cough, but the disease can progress to pneumonia in severe cases, especially when associated to comorbidities and fragile patients (e.g. hypertension, kidney failure, cancer, and diabetes). Elysium Cell Bio Ita in the Diagnostics area by using genome and functional genomics approaches develop a ready KIT to identify active SARS-COV-2 virus "spreaders", and identify  new therapeutics solutions using a Nutraceutical formula and new anti-viral drugs (Nutraceutics). The CE-IVD KIT  developed by Elysium is able to identify those patients with active viruses, as under anti-viral treatments, to verify the bonafide of the treatment and the prognosis of the COVID19 disease. This KIT was developed in collaboration with BioMol Laboratories- Naples- Italy. 

o   Identifying the “SPREADER” COVID19 patients: early detection of active replicative SARS-Cov-2 viruses

ELYSIUM Cell Bio ITA has designed a method to distinguish those patients infected by SARS-CoV-2 virus together with bioMol laboratories develop a kit INFECT-004 to detect subgenomic-N and ORF 1a-b and E and RNAse P in naso-oropharyngeal swab in a highly specific and sensitive way. The NAT" (Nucleic Acid Testing) molecular method: is a qualitative determination of the viral genome of SARS-CoV-2 (in order to identify patient with "active" SARS-CoV-2 viruses). This CE-IVD KIT INFET-004-100 RDM Code: 2218988/R was patented by Founders of Elysium Cell bio ITA Spin-Off of University of Naples and CEINGE Biotecnologie Avanzate – Naples- Italy srl 80145.

Download below the brochure of the product:

A patent related to this project: PCT/ EP2021/087512, “Method for determining Active SARS-Cov-2 infections”. was filed.